107 related articles for article (PubMed ID: 20876432)
1. Targeting patients for statin therapy for the primary prevention of vascular events: what is the best approach?
Mahoney EM
Circulation; 2010 Oct; 122(15):1446-8. PubMed ID: 20876432
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy.
Lee KK; Cipriano LE; Owens DK; Go AS; Hlatky MA
Circulation; 2010 Oct; 122(15):1478-87. PubMed ID: 20876434
[TBL] [Abstract][Full Text] [Related]
3. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
4. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
5. [Statines for all or individualized lipid lowering therapy?].
Parhofer K
MMW Fortschr Med; 2009 Apr; 151(14):100, 102-4; quiz 105. PubMed ID: 19504849
[No Abstract] [Full Text] [Related]
6. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
Fonseca FA; Izar MC
Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
[TBL] [Abstract][Full Text] [Related]
7. Statins for everyone--(even for those at low risk.) Experts are excited, but the question is whether benefits would outweigh costs.
Duke Med Health News; 2009 Feb; 15(2):1, 11. PubMed ID: 19358321
[No Abstract] [Full Text] [Related]
8. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
Kones R
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein levels and outcomes after statin therapy.
Jaber BL; Madias NE
N Engl J Med; 2005 Apr; 352(15):1603-5; author reply 1603-5. PubMed ID: 15832451
[No Abstract] [Full Text] [Related]
10. Drug insight: Statin use in the elderly.
Raffel OC; White HD
Nat Clin Pract Cardiovasc Med; 2006 Jun; 3(6):318-28. PubMed ID: 16729010
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction.
Ganz DA; Kuntz KM; Jacobson GA; Avorn J
Ann Intern Med; 2000 May; 132(10):780-7. PubMed ID: 10819700
[TBL] [Abstract][Full Text] [Related]
12. Relation of C-reactive protein and one-year survival after acute myocardial infarction with versus without statin therapy.
Kinjo K; Sato H; Sakata Y; Nakatani D; Mizuno H; Shimizu M; Nishino M; Ito H; Tanouchi J; Nanto S; Hori M;
Am J Cardiol; 2005 Sep; 96(5):617-21. PubMed ID: 16125481
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein levels and outcomes after statin therapy.
Cohen B; Singh D
N Engl J Med; 2005 Apr; 352(15):1603-5; author reply 1603-5. PubMed ID: 15829545
[No Abstract] [Full Text] [Related]
15. Lipids and stroke: looking for risk in all the wrong places?
Howard G; Goff DC
Ann Neurol; 2011 Apr; 69(4):597-9. PubMed ID: 21520228
[No Abstract] [Full Text] [Related]
16. C-reactive protein levels and outcomes after statin therapy.
Greenland P; Lloyd-Jones DM; Moss AJ
N Engl J Med; 2005 Apr; 352(15):1603-5; author reply 1603-5. PubMed ID: 15832450
[No Abstract] [Full Text] [Related]
17. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
18. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
van Hout BA; Simoons ML
Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.
Erickson KF; Japa S; Owens DK; Chertow GM; Garber AM; Goldhaber-Fiebert JD
J Am Coll Cardiol; 2013 Mar; 61(12):1250-8. PubMed ID: 23500327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
